The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker?

Urology

Volumn 48, Issue 6, 1996, Pages 971-979

  Heidenberg, Howard B ^a,b   Bauer, John J ^a,b   McLeod, David G ^a,b   Moul, Judd W ^a,b   Srivastava, Shiv ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; COMPLEMENTARY DNA; DNA; HORMONE; PHOSPHOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CHROMOSOME 17P; DNA REPAIR; DNA SEQUENCE; ETIOLOGY; GENE MUTATION; HUMAN; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR SUPPRESSOR GENE;

EID: 0030481099     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00365-2     Document Type: Article

References (66)

1. 1. Boring CC, Squires TS, and Tong T: Cancer statistics, 1993. CA Cancer J Clin 43: 7-26, 1993.
2. 2. Visakorpi T, Kallioniemi OP, Koivula T, and Isola J: New prognostic factors in prostatic carcinoma. Eur Urol 24: 438-449, 1993.
3. 3. Mostofi FK: Grading of prostatic carcinoma. Cancer Chemother Rep 59: 111, 1975.
4. 4. Lu-Yao GL, McLerran D, Wasson J, and Wennberg JE: An assessment of radical prostatectomy: time trends, geographical variation and outcomes: the Prostate Patient Outcomes Research Team. JAMA 269: 2633-2636, 1993.
5. 5. Hollstein M, Sidransky D, Vogelstein B, and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
6. 6. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
7. 7. Malkin D, Li FP, Strong LC, Fraumeni J Jr, Nelson CE, Lim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al: Germ line p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasms. Science 250: 1233-1238, 1990.
8. 8. Srivastava S, Zou ZQ, Blattner WA, and Chanh EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749, 1990.
9. 9. Malkin D: Germline p53 mutations and heritable cancer. Annu Rev Genet 28: 443-465, 1994.
10. 10. Issacs WB, Carter BS, and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
11. 11. Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, and Neal DE: p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 69: 609-613, 1992.
12. 12. Mellon K, Thompson S, Charlton RG, March C, et al: p53, c-erbB-2 and epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496-499, 1992.
13. 13. Effert PJ, McCoy RH, Walther PJ, and Liu ET: p53 gene alterations in human prostate carcinoma. J Urol 150: 257-261, 1993.
14. 14. Soini Y, Paakko P, Nuorva K, Kamel D, et al: Comparative analysis of p53 protein immunoreactivity in prostatic lung and breast carcinomas. Virchows Arch [A] 421: 223-228, 1992.
15. 15. Visakorpi T, Kallioniemi OP, Heikinen A, Koivula T, and Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
16. 16. Bookstein R, MacGrogan D, Hisenbeck SG, Sharkey F, and Allred DC: p53 mutated in a subset of advanced stage prostate cancers. Cancer Res 53: 3369-3373, 1993.
17. 17. Van Veidhuizen PJ, Sadasivan R, Garcia F, Austenfield MD, and Stephens RL: Mutant p53 expression in prostate carcinoma. Prostate 22: 23-30, 1993.
18. 18. Carroll AG, Voeller HJ, Sugars L, and Gelman EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23: 123-134, 1993.
19. 19. Hamdy CF, Thurrell W, Lawry J, Anderson JB, Parsons MA, Rees RC, and Royds J: p53 mutant expression in human prostatic adenocarcinoma. J Urol 149: 377A, 1993.
20. 20. Berner A, Nesland JM, Waehre H, Slide J, and Fossa SD: Hormone resistant prostatic adenocarcinoma: an evaluation of prognostic factors in pre-and post-treatment specimens. Br J Cancer 68: 380-384, 1993.
21. 21. Fox SB, Persad RA, Royds J, Korew RN, Silcocks PB, and Collins C: p53 and c-myc expression in stage A-1 prostatic adenocarcinoma: useful prognostic determinents? J Urol 150: 490-494, 1993.
22. 22. Navone NM, Troncoso P, Psiters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, and Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1659, 1993.
23. 23. Uchida T, Wada C, Shitara T, Egawa S, and Koshiba K: Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer. Br J Cancer 68: 751-755, 1993.
24. 24. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, and Neal DE: p53 expression and clinical outcome in prostate cancer. Br J Urol 72: 778-781, 1993.
25. 25. Kallakury BV, Figgie J, Leihovich B, Rifkin M, Kaufman R, Figgie HL, Nazeer T, and Ross JS: Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation (abstract 447). Mod Pathol 8: 78A, 1995.
26. 26. Zhang X, Colombel M, Raffo A, and Buttyan R: Enhanced expression of p53 mRNA and protein in regressing rate ventral prostate gland. Biochem Biophys Res Commun 198: 1189-1194, 1994.
27. 27. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, and Cordon-Cardo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151: 1276-1280, 1994.
28. 28. Berner A, Harvei S, Treti S, Fossa SD, and Nesland JM: Prostate carcinoma: a multivariate analysis of prognostic factors. Br J Cancer 69: 924-930, 1994.
29. 29. Dinjens WN, van der Weiden MM, Schroeder FH, Bosnian FT, and Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633, 1994.
30. 30. Chi SG, deVere-White RW, Meyers FJ, Siders DB, Lee F, and Gumerlock PH: p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86: 926-933, 1994.
31. 31. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, and Huland H: Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152: 1296-1301, 1994.
32. 32. Ittmann M, Wieczorek R, Helle P, Dave A, Provet J, and Krolewski J: Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 145: 287-293, 1994.
33. 33. Voeller HJ, Sugars LY, Pretloe T, and Gelman EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994.
34. 34. Shurbaji MS, Kalbfeisch JH, and Thurmond TS: Immunohistochemical detection of p53 protein and a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109, 1995.
35. 35. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, and Chung LW: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45: 470-475, 1995.
36. 36. Berner A, Greitvik G, Karlsen F, Fossa SD, Nesland JM, and Borresan AL: p53 mutations in prostatic cancer: analysis of pre-and post-treatment archival formalin-fixed tumor tissue. J Pathol 176: 294-308, 1995.
37. 37. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, and Roy-Burman P: Heterogenerity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147: 92-101, 1995.
38. 38. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Darrenberg K, et al: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27: 18-24, 1995.
39. 39. Heidenberg HB, Sesterhenn IA, Gaddipati P, Weghorst CM, Buzard GS, Moul JW, and Srivastava S: Alterations of the tumor suppressor gene p53 in a high fraction of treatment resistant prostate cancer. J Urol 154: 414-421, 1995.
40. 40. Zambetti DR, and Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865, 1993.
41. 41. Harris CC, and Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329: 1318-1327, 1993.
42. 42. Nigro J, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
43. 43. Leonard CJ, Canman CE, and Kaston MB: The role of p53 in cell cycle control and apoptosis: implications for cancer, in DeVita VT, Hellman S, and Rosenberg SA (Eds): Important Advances in Oncology, Philadelphia, JB Lippincott Company, 1995, pp 33-42.
44. 44. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, et al: p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337, 1994.
45. 45. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, and McDonnell TJ: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9: 3107-3112, 1994.
46. 46. Donehower LA, Harvey M, Slagle BI, McArthur MJ, Montgomery CA Jr, Butel JS, and Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221, 1992.
47. 47. Yonish-Rouach LE, Rewnitzky D, Lotern J, Kinchi A, and Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that are inhibited by interleukin-6. Nature 353: 345-347, 1991.
48. 48. Silvestrini R, Verneroni S, Daidone MG, Bernie E, Boarabi P, Mezzetti M, DiFronzo G, Rilke F, and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 449-504, 1994.
49. 49. Haldar S, Negrini M, Monne M, Sabbioni S, and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
50. 50. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, and Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-Xl and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
51. 51. Kyprianou N, Bains AK, and Jacobs SC: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 25: 66-75, 1994.
52. 52. Berges RR, Furuya Y, Remington L, English HF, Jacks T, and Issacs J: Cell proliferation, DNA repair, and p53 function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90: 8910-8914, 1993.
53. 53. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, Chopin D, and Thiery JP: Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 10: 1269-1274, 1995.
54. 54. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, and Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 156: 1511-1516, 1996.
55. 55. Gousse AE, Tobon AA, Eastham JA, Slawin KM, Wheeler TM, Scardino PT, and Thompson TC: Clonal expansion of p53 mutations at metastatic sites in clinical prostate cancer: an analysis using TA-SSCP (abstract 970). J Urol 153: 471A, 1995.
56. 56. Stricker HJ, Jay JK, Linder MD, Tamboli P, and Amin MB: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 47: 366-369, 1996.
57. 57. Van Veldhuizen PZ, Sadasivan R, Cherian R, Dwyer T, and Stephens RL: p53 expression in incidental prostatic cancer. Am J Med Sci 305: 275-279, 1993.
58. 58. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, and Moul JW: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1: 1295-1300, 1995.
59. 59. Yang G, Stapleton AMF, Wheeler TM, Truong LD, Timme TL, Scardino PT, and Thompson TC: Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2: 399-401, 1996.
60. 60. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, and Moul JW: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 156: 1064-1068, 1996.
61. 61. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, and Yang G: Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene 10: 869-879, 1995.
62. 62. Issacs WB, Robinson JC, Carmichael M, and Epstein JL: p53 expression in prostate cancer metastasis: correlation with progression (abstract 236). J Urol 286A, 1994.
63. 63. Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul JW, Cowan K, and Seth P: Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46: 843-848, 1995.
64. 64. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJU, Zhang WW, Harper JW, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
65. 65. Yang C, Cirielli C, Capogrossi MC, and Passaniti A: Adenovirus mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of prostate tumor cells. Cancer Res 55: 4210-4213, 1995.
66. 66. Asgari K, Tong Y-A, Sesterhenn I, Moul JW, McLeod DG, Seth P, and Srivastava S: Evaluation of gene therapy potential of a recombinant adenovirus p53 expression vector in pre-established tumor nodules of prostate cancer in nude mice. Proceedings of the American Association for Cancer Research, Washington, DC. 37: Abstract No. 2416, 1996.